140Safety, tolerability and drug interactions of adjuvant imatinib mesylate (GLEEVEC®) within the first 100 days following stem cell transplantation (SCT) in patients with PH+ CML and PH+ all at high risk for recurrence

Autor:	Cindy Ippoliti, Paolo Anderlini, S.R. Sheth, Sergio Giralt, K. Hicks, Richard E. Champlin
Rok vydání:	2003
Předmět:	Drug Transplantation business.industry medicine.medical_treatment media_common.quotation_subject Hematology Pharmacology Imatinib mesylate Tolerability Medicine In patient Stem cell business Adjuvant media_common
Zdroj:	Biology of Blood and Marrow Transplantation. 9:107
ISSN:	1083-8791
DOI:	10.1016/s1083-8791(03)80141-6
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c2a7f95ef35ad21e7c229a2ace1dd59 https://doi.org/10.1016/s1083-8791(03)80141-6 Zobrazit plný text záznamu Full Text from ScienceDirect